NCT05902962View on ClinicalTrials.gov

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

August 30, 2025

Conditions
Retinal DystrophyPRPF31 Mutationassociated Retinal DystrophyRP11
Interventions
DRUG

VP-001

Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy

Trial Locations (6)

32209

University of Florida Health, Jacksonville

33136

Bascom Palmer Eye Institute University of Miami, Miami

48105

University of Michigan Kellogg Eye Center, Ann Arbor

75321

Retina Foundation of the Southwest, Dallas

77030

Baylor College of Medicine- Alkek Eye Center, Houston

97239

Oregon Health and Science University - Casey Eye Institute, Portland

Sponsors

Lead Sponsor

PYC Therapeutics
All Listed Sponsors
lead

PYC Therapeutics

INDUSTRY

NCT05902962 - SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects | Biotech Hunter | Biotech Hunter